
Sign up to save your podcasts
Or


Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content:
By JAMA Network4.4
472472 ratings
Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content:

321 Listeners

549 Listeners

701 Listeners

163 Listeners

260 Listeners

906 Listeners

3,374 Listeners

38 Listeners

21 Listeners

16 Listeners

11 Listeners

8 Listeners

17 Listeners

19 Listeners

5 Listeners

6 Listeners

1,150 Listeners

31 Listeners

9 Listeners

94 Listeners

141 Listeners

14 Listeners

5 Listeners

518 Listeners

5 Listeners

367 Listeners

260 Listeners

437 Listeners

106 Listeners

18 Listeners

320 Listeners

2 Listeners

325 Listeners

270 Listeners